← All Harvard Bioscience INC filings

Harvard Bioscience INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
HBIO
Harvard Bioscience INC
10-K: Harvard Bioscience Reports 2025 Loss, Strategic Restructuring
Harvard Bioscience, Inc. reported a significant net loss in 2025, driven by goodwill impairment and declining revenues, while initiating a major manufacturing consolidation and debt refinancing.
NASDAQ
HBIO
Harvard Bioscience INC
10-K: Harvard Bioscience Faces Going Concern Uncertainty Amidst Debt Covenant Breach and Refinancing Efforts
Harvard Bioscience's 2024 10-K filing reveals substantial doubt about the company's ability to continue as a going concern due to a debt covenant breach and the need to refinance its credit agreement by June 30, 2025.
NASDAQ
HBIO
Harvard Bioscience INC
10-K: Harvard Bioscience Reports Mixed Results in 2023 Annual Filing, Focuses on Strategic Growth
Harvard Bioscience's 2023 annual report reveals a slight revenue decrease but improved gross profit margins, alongside strategic shifts and restructuring efforts.